CD133 Expression and Cancer Stem Cells Predict Prognosis in High‐grade Oligodendroglial Tumors

High‐grade oligodendroglial tumors, that is, anaplastic oligodendroglial tumors and glioblastomas with oligodendroglial component, differ significantly in terms of prognosis and response to chemotherapy. Differentiation might be difficult because the histological differences are vague and reliable m...

Full description

Saved in:
Bibliographic Details
Published in:Brain pathology (Zurich, Switzerland) Switzerland), 2008-07, Vol.18 (3), p.370-377
Main Authors: Beier, Dagmar, Wischhusen, Jörg, Dietmaier, Wolfgang, Hau, Peter, Proescholdt, Martin, Brawanski, Alexander, Bogdahn, Ulrich, Beier, Christoph P.
Format: Article
Language:English
Subjects:
AC133 Antigen
Antigens, CD - biosynthesis
Biomarkers, Tumor - analysis
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
cancer stem cells
CD133
Flow Cytometry
Glioma - metabolism
Glioma - pathology
Glycoproteins - biosynthesis
Humans
Immunohistochemistry
Neoplastic Stem Cells - metabolism
oligodendroglial tumor
Oligonucleotide Array Sequence Analysis
Peptides
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High‐grade oligodendroglial tumors, that is, anaplastic oligodendroglial tumors and glioblastomas with oligodendroglial component, differ significantly in terms of prognosis and response to chemotherapy. Differentiation might be difficult because the histological differences are vague and reliable markers are not established. We correlated the presence of putative cancer stem cells (CSC) in high‐grade oligodendroglial tumors (WHO grades III and IV) with clinical outcome. Tumors with favorable prognosis neither contained CSC nor did they show CD133 expression. Tumor cells resembled lineage‐restricted progenitor cells with limited proliferative capacity and differentiation profile. In contrast, CD133 expression and stem cell‐like tumor cells characterized tumors with poor prognosis. They showed neurosphere‐like growth, differentiated into cells of all neural lineages, and were tumorigenic in nude mice. In our series, CSC and expression of CD133 predicted the clinical course of disease better than the histological grading. To confirm these results, we retrospectively analyzed 36 high‐grade oligodendroglial tumors. Again, CD133 expression indicated shorter survival and predicted clinical outcome more reliable than the histological assessment. Our data show that detection of CSC and expression of CD133 is predictive of prognosis in high‐grade oligodendroglial tumors. The presence or absence of CD133+ CSC might explain the crucial biological difference between WHO grade III and IV oligodendroglial tumors.
ISSN:1015-6305
1750-3639
DOI:10.1111/j.1750-3639.2008.00130.x